Under DZP Future, we have supported a leader in the use of AI in reproductive medicine

MIM Fertility is an innovative project using artificial intelligence to improve infertility treatment outcomes. Thanks to their advanced platforms EMBRYOAID and FOLLISCAN, which are based on AI software, a detailed analysis is carried out of ovarian follicles and an accurate assessment is made of embryo quality. This solution provides effective support to specialists in addressing reproductive health issues.

The startup concluded a seed round, raising USD 2 million in funding from investors (Tangent Line and Peleton), which it is planning to use to further develop the technology and introduce new platform functionalities. It will also raise the company's profile on international markets.

The advice was provided by Maciej Zajda and Katarzyna Biarda, who supported MIM Fertility throughout the negotiations and the preparation of the investment agreement. The lawyers supported the startup under the DZP Future programme, which is aimed at innovative initiatives and the most promising companies with high growth potential. The programme offers startups the best advisory support at every stage of their development. DZP's experts help innovative companies, e.g. set up a company, hire employees and raise financing for product development.